Latest Update: Impact of current COVID-19 situation has been considered in this report while making the analysis.
Global Lopinavir and Ritonavir Market by Type (Tablet, Capsule, Oral solution), By Application (Adults, Children 14 days of age and older) And By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030-report

Global Lopinavir and Ritonavir Market by Type (Tablet, Capsule, Oral solution), By Application (Adults, Children 14 days of age and older) And By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030

Report ID: 130346 3300 Pharma & Healthcare 377 232 Pages 4.9 (47)

Market Overview:

The global lopinavir and ritonavir market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of HIV/AIDS, rising demand for better treatment options, and growing investments in R&D. By type, the global lopinavir and ritonavir market is segmented into tablet, capsule, and oral solution. The tablet segment is expected to account for the largest share of the global lopinavir and ritonavir market in 2018. By application, adults accounted for the majority share of the global lopinavir and ritonavir market in 2017. However, children 14 days of age or older are expected to witness higher growth during the forecast period owing to increasing awareness about HIV/AIDS prevention among parents across regions. to increase numberof people infected with HIV virus .

Global Lopinavir and Ritonavir Industry Outlook

Product Definition:

Lopinavir and ritonavir are antiretroviral medications used to treat HIV infection. They are a protease inhibitor combination pill. Lopinavir and ritonavir work by decreasing the amount of HIV in the body.


Tablet is a form of oral medication that is taken by mouth. It comes in different shapes and sizes, which can be defined by the type of drug they contain. For example, Tylenol 3 contains codeine while Adderall contains bothcodeine and amphetamine.


Capsule is a small package containing medicine and it is used to protect medicines from harmful effects of light, temperature, moisture, and air. Capsules are available in different sizes and shapes which help in protecting the medicines for a longer duration. Lopinavir & ritonavir capsules are made up of gelatin and are colorless & amp;;lt;; They come with an enteric coating that protects them from stomach acidity.

Application Insights:

The adults segment held the largest share of over 70.0% in 2017. The use of lopinavir and ritonavir for the treatment of HIV has been approved by the U.S FDA and other regulatory authorities for use in adults, thus driving its demand among adult patients globally. Moreover, increasing awareness about these two drugs amongst patients suffering from HIV is also expected to drive their demand among adult population globally during forecast period.

The children 14 days age group segment is expected to grow at a significant rate owing to rising awareness about immunization against various diseases including chickenpox, typhoid, cholera etc., which was previously controlled by parents through natural immunity acquired during childhood infections i.e.

Regional Analysis:

North America dominated the global market in terms of revenue in 2017. The presence of a large number of manufacturers coupled with high awareness levels and availability of branded generics are some factors responsible for its largest share. Furthermore, increasing cases of HIV/AIDS have led to an increase in demand for these drugs, which is expected to drive growth over the forecast period.

Asia Pacific is anticipated to be one of the fastest-growing regions owing to rising disposable income and improving healthcare infrastructure especially in developing countries such as India and China. Increasing investments by major players on expanding their manufacturing facilities will also contribute towards regional growth over the forecast period.

Growth Factors:

  • Increasing prevalence of HIV/AIDS: The number of people infected with HIV is increasing at a rapid pace, which is expected to drive the demand for Lopinavir and Ritonavir in the coming years.
  • Rising awareness about antiretroviral drugs: There is a growing awareness among people about the benefits of using antiretroviral drugs, which is likely to boost the demand for Lopinavir and Ritonavir in the near future.
  • Growing investment in healthcare sector: A number of governments are investing heavily in healthcare sector, which is anticipated to create lucrative opportunities for players operating in Lopinavir and Ritonavir market over the forecast period.
  • Technological advancements: The introduction of novel technologies such as point-of-care testing (POCT) will help improve diagnosis rates for HIV/AIDS patients, thereby propelling growth prospects for Lopinavir and Ritonavir market during forecast period. 5

Scope Of The Report

Report Attributes

Report Details

Report Title

Lopinavir and Ritonavir Market Research Report

By Type

Tablet, Capsule, Oral solution

By Application

Adults, Children 14 days of age and older

By Companies

AbbVie, Lannett, Cipla, Mylan, Aurobindo Pharma, HETERO, MACLEODS, ...

Regions Covered

North America, Europe, APAC, Latin America, MEA

Base Year


Historical Year

2019 to 2020 (Data from 2010 can be provided as per availability)

Forecast Year


Number of Pages


Number of Tables & Figures


Customization Available

Yes, the report can be customized as per your need.

Global Lopinavir and Ritonavir Market Report Segments:

The global Lopinavir and Ritonavir market is segmented on the basis of:


Tablet, Capsule, Oral solution

The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.


Adults, Children 14 days of age and older

The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.

Some of the companies that are profiled in this report are:

  1. AbbVie
  2. Lannett
  3. Cipla
  4. Mylan
  5. Aurobindo Pharma
  8. ...

Global Lopinavir and Ritonavir Market Overview

Highlights of The Lopinavir and Ritonavir Market Report:

  1. The market structure and projections for the coming years.
  2. Drivers, restraints, opportunities, and current trends of market.
  3. Historical data and forecast.
  4. Estimations for the forecast period 2030.
  5. Developments and trends in the market.
  6. By Type:

    1. Tablet
    2. Capsule
    3. Oral solution
  1. By Application:

    1. Adults
    2. Children 14 days of age and older
  1. Market scenario by region, sub-region, and country.
  2. Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
  3. Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
  4. Government Policies, Macro & Micro economic factors are also included in the report.

We have studied the Lopinavir and Ritonavir Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.

Regional Analysis

  • North America
  • Europe
  • Asia Pacific
  • Middle East & Africa
  • Latin America

Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.

The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.

How you may use our products:

  • Correctly Positioning New Products
  • Market Entry Strategies
  • Business Expansion Strategies
  • Consumer Insights
  • Understanding Competition Scenario
  • Product & Brand Management
  • Channel & Customer Management
  • Identifying Appropriate Advertising Appeals

Global Lopinavir and Ritonavir Market Statistics

8 Reasons to Buy This Report

  1. Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
  2. Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
  3. Implemented Robust Methodology to Prepare the Report
  4. Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
  5. Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
  6. Provides Information About the Top-winning Strategies Implemented by Industry Players.
  7. In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
  8. Customization of the Report Available

Frequently Asked Questions?

Lopinavir and ritonavir are antiviral medications used to treat HIV. Lopinavir is a nucleoside reverse transcriptase inhibitor (NRTI) and ritonavir is an NNRTI. Together, they work by blocking the virus from replicating in the body.

Some of the major players in the lopinavir and ritonavir market are AbbVie, Lannett, Cipla, Mylan, Aurobindo Pharma, HETERO, MACLEODS.

1. Executive Summary

2. Assumptions and Acronyms Used

3. Research Methodology

4. Lopinavir and Ritonavir Market Overview
   4.1. Introduction
      4.1.1. Market Taxonomy
      4.1.2. Market Definition
   4.2. Macro-Economic Factors
      4.2.1. Industry Outlook
   4.3. Lopinavir and Ritonavir Market Dynamics
      4.3.1. Market Drivers
      4.3.2. Market Restraints
      4.3.3. Opportunity
      4.3.4. Market Trends
   4.4. Lopinavir and Ritonavir Market - Supply Chain
   4.5. Global Lopinavir and Ritonavir Market Forecast
      4.5.1. Lopinavir and Ritonavir Market Size (US$ Mn) and Y-o-Y Growth
      4.5.2. Lopinavir and Ritonavir Market Size (000’ Units) and Y-o-Y Growth
      4.5.3. Lopinavir and Ritonavir Market Absolute $ Opportunity

5. Global Lopinavir and Ritonavir Market Analysis and Forecast by Type
   5.1. Market Trends
   5.2. Introduction
      5.2.1. Basis Point Share (BPS) Analysis by Type
      5.2.2. Y-o-Y Growth Projections by Type
   5.3. Lopinavir and Ritonavir Market Size and Volume Forecast by Type
      5.3.1. Tablet
      5.3.2. Capsule
      5.3.3. Oral solution
   5.4. Absolute $ Opportunity Assessment by Type
   5.5. Market Attractiveness/Growth Potential Analysis by Type

6. Global Lopinavir and Ritonavir Market Analysis and Forecast by Application
   6.1. Market Trends
   6.2. Introduction
      6.2.1. Basis Point Share (BPS) Analysis by Application
      6.2.2. Y-o-Y Growth Projections by Application
   6.3. Lopinavir and Ritonavir Market Size and Volume Forecast by Application
      6.3.1. Adults
      6.3.2. Children 14 days of age and older
   6.4. Absolute $ Opportunity Assessment by Application
   6.5. Market Attractiveness/Growth Potential Analysis by Application

7. Global Lopinavir and Ritonavir Market Analysis and Forecast by Sales Channel
   7.1. Market Trends
   7.2. Introduction
      7.2.1. Basis Point Share (BPS) Analysis by Sales Channel 
      7.2.2. Y-o-Y Growth Projections by Sales Channel
   7.3. Lopinavir and Ritonavir Market Size and Volume Forecast by Sales Channel 
      7.3.1. Manufacturer/Distributor/Service Provider
      7.3.2. Aftermarket
   7.4. Absolute $ Opportunity Assessment by Sales Channel
   7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel

8. Global Lopinavir and Ritonavir Market Analysis and Forecast by Region
   8.1. Market Trends
   8.2. Introduction
      8.2.1. Basis Point Share (BPS) Analysis by Region
      8.2.2. Y-o-Y Growth Projections by Region
   8.3. Lopinavir and Ritonavir Market Size and Volume Forecast by Region
      8.3.1. North America
      8.3.2. Latin America
      8.3.3. Europe
      8.3.4. Asia Pacific
      8.3.5. Middle East and Africa (MEA)
   8.4. Absolute $ Opportunity Assessment by Region
   8.5. Market Attractiveness/Growth Potential Analysis by Region
   8.6. Global Lopinavir and Ritonavir Demand Share Forecast, 2019-2029

9. North America Lopinavir and Ritonavir Market Analysis and Forecast
   9.1. Introduction
      9.1.1. Basis Point Share (BPS) Analysis by Country
      9.1.2. Y-o-Y Growth Projections by Country
   9.2. North America Lopinavir and Ritonavir Market Size and Volume Forecast by Country
      9.2.1. U.S.
      9.2.2. Canada
   9.3. Absolute $ Opportunity Assessment by Country
   9.4. North America Lopinavir and Ritonavir Market Size and Volume Forecast by Application
      9.4.1. Adults
      9.4.2. Children 14 days of age and older
   9.5. Basis Point Share (BPS) Analysis by Application
   9.6. Y-o-Y Growth Projections by Application
   9.7. North America Lopinavir and Ritonavir Market Size and Volume Forecast by Type
      9.7.1. Tablet
      9.7.2. Capsule
      9.7.3. Oral solution
   9.8. Basis Point Share (BPS) Analysis by Type
   9.9. Y-o-Y Growth Projections by Type
   9.10. Market Attractiveness/Growth Potential Analysis
      9.10.1. By Country
      9.10.2. By Product Type
      9.10.3. By Application
      9.10.4. By Sales Channel
   9.11. North America Lopinavir and Ritonavir Demand Share Forecast, 2019-2029

10. Latin America Lopinavir and Ritonavir Market Analysis and Forecast
   10.1. Introduction
      10.1.1. Basis Point Share (BPS) Analysis by Country
      10.1.2. Y-o-Y Growth Projections by Country
      10.1.3. Latin America Average Pricing Analysis
   10.2. Latin America Lopinavir and Ritonavir Market Size and Volume Forecast by Country
      10.2.1. Brazil
      10.2.2. Mexico
      10.2.3. Rest of Latin America
   10.3. Absolute $ Opportunity Assessment by Country
   10.4. Latin America Lopinavir and Ritonavir Market Size and Volume Forecast by Application
      10.4.1. Adults
      10.4.2. Children 14 days of age and older
   10.5. Basis Point Share (BPS) Analysis by Application
   10.6. Y-o-Y Growth Projections by Application
   10.7. Latin America Lopinavir and Ritonavir Market Size and Volume Forecast by Type
      10.7.1. Tablet
      10.7.2. Capsule
      10.7.3. Oral solution
   10.8. Basis Point Share (BPS) Analysis by Type
   10.9. Y-o-Y Growth Projections by Type
   10.10. Market Attractiveness/Growth Potential Analysis
      10.10.1. By Country
      10.10.2. By Product Type
      10.10.3. By Application
      10.10.4. By Sales Channel
   10.11. Latin America Lopinavir and Ritonavir Demand Share Forecast, 2019-2029

11. Europe Lopinavir and Ritonavir Market Analysis and Forecast
   11.1. Introduction
      11.1.1. Basis Point Share (BPS) Analysis by Country
      11.1.2. Y-o-Y Growth Projections by Country
      11.1.3. Europe Average Pricing Analysis
   11.2. Europe Lopinavir and Ritonavir Market Size and Volume Forecast by Country
      11.2.1. Germany
      11.2.2. France
      11.2.3. Italy
      11.2.4. U.K.
      11.2.5. Spain
      11.2.6. Russia
      11.2.7. Rest of Europe
   11.3. Absolute $ Opportunity Assessment by Country
   11.4. Europe Lopinavir and Ritonavir Market Size and Volume Forecast by Application
      11.4.1. Adults
      11.4.2. Children 14 days of age and older
   11.5. Basis Point Share (BPS) Analysis by Application
   11.6. Y-o-Y Growth Projections by Application
   11.7. Europe Lopinavir and Ritonavir Market Size and Volume Forecast by Type
      11.7.1. Tablet
      11.7.2. Capsule
      11.7.3. Oral solution
   11.8. Basis Point Share (BPS) Analysis by Type
   11.9. Y-o-Y Growth Projections by Type
   11.10. Market Attractiveness/Growth Potential Analysis
      11.10.1. By Country
      11.10.2. By Product Type
      11.10.3. By Application
      11.10.4. By Sales Channel
   11.11. Europe Lopinavir and Ritonavir Demand Share, 2019-2029

12. Asia Pacific Lopinavir and Ritonavir Market Analysis and Forecast
   12.1. Introduction
      12.1.1. Basis Point Share (BPS) Analysis by Country
      12.1.2. Y-o-Y Growth Projections by Country
      12.1.3. Asia Pacific Average Pricing Analysis
   12.2. Asia Pacific Lopinavir and Ritonavir Market Size and Volume Forecast by Country
      12.2.1. China
      12.2.2. Japan
      12.2.3. South Korea
      12.2.4. India
      12.2.5. Australia
      12.2.6. Rest of Asia Pacific (APAC)
   12.3. Absolute $ Opportunity Assessment by Country
   12.4. Asia Pacific Lopinavir and Ritonavir Market Size and Volume Forecast by Application
      12.4.1. Adults
      12.4.2. Children 14 days of age and older
   12.5. Basis Point Share (BPS) Analysis by Application
   12.6. Y-o-Y Growth Projections by Application
   12.7. Asia Pacific Lopinavir and Ritonavir Market Size and Volume Forecast by Type
      12.7.1. Tablet
      12.7.2. Capsule
      12.7.3. Oral solution
   12.8. Basis Point Share (BPS) Analysis by Type
   12.9. Y-o-Y Growth Projections by Type
   12.10. Market Attractiveness/Growth Potential Analysis
      12.10.1. By Country
      12.10.2. By Product Type
      12.10.3. By Application
      12.10.4. By Sales Channel
   12.11. Asia Pacific Lopinavir and Ritonavir Demand Share, 2019-2029

13. Middle East & Africa Lopinavir and Ritonavir Market Analysis and Forecast
   13.1. Introduction
      13.1.1. Basis Point Share (BPS) Analysis by Country
      13.1.2. Y-o-Y Growth Projections by Country
      13.1.3. Asia Pacific Average Pricing Analysis
   13.2. Middle East & Africa Lopinavir and Ritonavir Market Size and Volume Forecast by Country
      13.2.1. Saudi Arabia
      13.2.2. South Africa
      13.2.3. UAE
      13.2.4. Rest of Middle East & Africa (MEA)
   13.3. Absolute $ Opportunity Assessment by Country
   13.4. Middle East & Africa Lopinavir and Ritonavir Market Size and Volume Forecast by Application
      13.4.1. Adults
      13.4.2. Children 14 days of age and older
   13.5. Basis Point Share (BPS) Analysis by Application
   13.6. Y-o-Y Growth Projections by Application
   13.7. Middle East & Africa Lopinavir and Ritonavir Market Size and Volume Forecast by Type
      13.7.1. Tablet
      13.7.2. Capsule
      13.7.3. Oral solution
   13.8. Basis Point Share (BPS) Analysis by Type
   13.9. Y-o-Y Growth Projections by Type
   13.10. Market Attractiveness/Growth Potential Analysis
      13.10.1. By Country
      13.10.2. By Product Type
      13.10.3. By Application
      13.10.4. By Sales Channel
   13.11. Middle East & Africa Lopinavir and Ritonavir Demand Share, 2019-2029

14. Competition Landscape
   14.1. Global Lopinavir and Ritonavir Market: Market Share Analysis
   14.2. Lopinavir and Ritonavir Distributors and Customers
   14.3. Lopinavir and Ritonavir Market: Competitive Dashboard
   14.4. Company Profiles (Details – Overview, Financials, Developments, Strategy) 
      14.4.1. AbbVie Overview Financials Developments Strategic Outlook
      14.4.2. Lannett Overview Financials Developments Strategic Outlook
      14.4.3. Cipla Overview Financials Developments Strategic Outlook
      14.4.4. Mylan Overview Financials Developments Strategic Outlook
      14.4.5. Aurobindo Pharma Overview Financials Developments Strategic Outlook
      14.4.6. HETERO Overview Financials Developments Strategic Outlook
      14.4.7. MACLEODS Overview Financials Developments Strategic Outlook
      14.4.8. ... Overview Financials Developments Strategic Outlook
      14.4.9. COMPANY9 Overview Financials Developments Strategic Outlook
      14.4.10. COMPANY 10 Overview Financials Developments Strategic Outlook
      14.4.11. COMPANY 11 Overview Financials Developments Strategic Outlook
      14.4.12. COMPANY 12 Overview Financials Developments Strategic Outlook
      14.4.13. COMPANY 13 Overview Financials Developments Strategic Outlook
      14.4.14. COMPANY 14 Overview Financials Developments Strategic Outlook
      14.4.15. COMPANY 15 Overview Financials Developments Strategic Outlook
      14.4.16. COMPANY 16 Overview Financials Developments Strategic Outlook
      14.4.17. COMPANY 17 Overview Financials Developments Strategic Outlook
      14.4.18. COMPANY 18 Overview Financials Developments Strategic Outlook
      14.4.19. COMPANY 19 Overview Financials Developments Strategic Outlook
      14.4.20. COMPANY 20 Overview Financials Developments Strategic Outlook

Our Trusted Clients

Contact Us